This report was first published by Endpoints News. To see the original version, click here
Priovant Therapeutics, a Roivant spinout, announced that an experimental immune drug it inherited from Pfizer succeeded in a Phase 2 trial for cutaneous sarcoidosis, a rare condition that causes small bumps or lesions to form on the skin.
Priovant said that it plans to start a Phase 3 trial this year. Cutaneous sarcoidosis marks the third condition in which the company is aiming to advance brepocitinib, an inhibitor of two well-known immune disease targets: JAK1 and TYK2.
您已阅读15%（565字），剩余85%（3103字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。